ReviewCurrent medicinal chemistry2013
Canonical and non-canonical barriers facing antimiR cancer therapeutics.
Review in Current medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Targeting non-coding RNA family members with artificial endonuclease XNAzymes.Communications biology · 2022Article
- Therapeutic Potential of Chemically Modified, Synthetic, Triplex Peptide Nucleic Acid-Based Oncomir Inhibitors for Cancer Therapy.Cancer research · 2021Article
- MiRNAs and Muscle Regeneration: Therapeutic Targets in Duchenne Muscular Dystrophy.International journal of molecular sciences · 2021Review
- Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application.Current neuropharmacology · 2020Review
- Article
- Extracellular vesicles show promise for cancer theranostics.Annals of translational medicine · 2019Article
- Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).Oncotarget · 2018Article
- Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities.The Yale journal of biology and medicine · 2017Review
- Article
- miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.Scientific reports · 2017Article
- Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells.Functional & integrative genomics · 2017Article
- Dual Functional Roles of Molecular Beacon as a MicroRNA Detector and Inhibitor.The Journal of biological chemistry · 2017Article
- MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers.PPAR research · 2017Review
- Pigmy MicroRNA: surveillance cops in Therapies kingdom.Molecular medicine (Cambridge, Mass.) · 2016Article
- Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.Oncotarget · 2016Article
- The Role of miRNAs in Common Inflammatory Arthropathies: Osteoarthritis and Gouty Arthritis.Biomolecules · 2016Review
- miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.Cancer discovery · 2016Review
- MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.Frontiers in pharmacology · 2016Review
- miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.Molecular endocrinology (Baltimore, Md.) · 2015Article
- Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.Nano letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Once considered genetic "oddities", microRNAs (miRNAs) are now recognized as key epigenetic regulators of numerous biological processes, including some with a causal link to the pathogenesis, maintenance, and treatment of cancer. The crux of small RNA-based therapeutics lies in the antagonism of potent cellular targets; the main shortcoming of the field in general, lies in ineffective delivery. Inhibition of oncogenic miRNAs is a relatively nascent therapeutic concept, but as with predecessor RNA-based therapies, success hinges on delivery efficacy. This review will describes the canonical (e.g. pharmacokinetics and clearance, cellular uptake, endosome escape, etc.) and non-canonical (e.g. spatial localization and accessibility of miRNA, technical limitations of miRNA inhibition, off-target impacts, etc.) challenges to the delivery of antisense-based anti-miRNA therapeutics (i.e. antimiRs) for the treatment of cancer. Emphasis will be placed on how the current leading antimiR platforms-ranging from naked chemically modified oligonucleotides to nanoscale delivery vehicles-are affected by and overcome these barriers. The perplexity of antimiR delivery presents both engineering and biological hurdles that must be overcome in order to capitalize on the extensive pharmacological benefits of antagonizing tumor-associated miRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.